Neurological outcome of long-term glioblastoma survivors Journal Article
| Authors: | Hottinger, A. F.; Yoon, H.; Deangelis, L. M.; Abrey, L. E. |
| Article Title: | Neurological outcome of long-term glioblastoma survivors |
| Abstract: | Extended survival of 3 or more years is rare in patients with glioblastoma (GBM) but is becoming more common. Clinical outcome has not been well studied. We reviewed GBM patients at Memorial Sloan-Kettering Cancer Center between 2001 and 2003 who were seen for two or more visits. Patient characteristics and long-term clinical outcomes were reviewed for patients who had survived 3 or more years following diagnosis. Thirty-nine (11%) of 352 GBM patients were identified as long-term survivors. Median survival was 9.15 years (range: 3-18 years). Median age was 47 years (range: 16-69); 13% were 65 years or older. Median KPS was 90 (range: 50-100). One long-term survivor underwent biopsy alone; 19 patients each had either complete or subtotal resection. All received focal radiotherapy (RT) with a median dose of 5940 cGy; 18% received concurrent temozolomide. Adjuvant chemotherapy was administered to 35 (90%). Twelve patients (31%) remained in continuous remission. Twenty-seven had tumor progression a median of 29.2 months after diagnosis (range: 1.2-167 months); 18 had multiple relapses. Median KPS at last follow-up was 70 (range: 40-100); 85% of long-term survivors had at least one significant neurologic deficit. Eleven (28%) had clinically significant RT-induced leukoencephalopathy, 9 (23%) developed RT necrosis and 9 (23%) treatment-related strokes. Treatment-related complications occurred a median of 2.7 years from diagnosis (range: 0.9-11.5 years). Long-term survivors remain rare, but are found across all age groups despite multiple recurrences; clinically significant delayed complications of treatment are common. © 2009 Springer Science+Business Media, LLC. |
| Keywords: | adolescent; adult; cancer survival; clinical article; treatment outcome; aged; middle aged; survival analysis; cancer surgery; retrospective studies; young adult; review; cisplatin; cancer adjuvant therapy; cancer radiotherapy; radiation dose; temozolomide; follow up; brain neoplasms; follow-up studies; quality of life; neoplasm recurrence, local; vincristine; tumor biopsy; carmustine; lomustine; procarbazine; cancer survivor; survivors; cancer regression; karnofsky performance status; stroke; glioblastoma; tipifarnib; long term care; cancer relapse; cancer control; cognition disorders; databases, factual; neurologic disease; long-term survivors; hearing loss; leukoencephalopathy; radiation necrosis |
| Journal Title: | Journal of Neuro-Oncology |
| Volume: | 95 |
| Issue: | 3 |
| ISSN: | 0167-594X |
| Publisher: | Springer |
| Date Published: | 2009-12-01 |
| Start Page: | 301 |
| End Page: | 305 |
| Language: | English |
| DOI: | 10.1007/s11060-009-9946-9 |
| PUBMED: | 19557499 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 4" - "Export Date: 30 November 2010" - "CODEN: JNODD" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
576De Angelis -
14Hottinger -
278
Abrey -
2
Yoon
Related MSK Work